Alfred, T and Ben-Shlomo, Y and Cooper, R and Hardy, R and Cooper, C and Deary, IJ and Elliott, J and Gunnell, D and Harris, SE and Kivimaki, M and Kumari, M and Martin, RM and Power, C and Sayer, AA and Starr, JM and Kuh, D and Day, IN and Team, HALCyon Study (2014) Associations between APOE and low-density lipoprotein cholesterol genotypes and cognitive and physical capability: the HALCyon programme. AGE, 36 (4). ISSN 0161-9152

Downloaded from: http://e-space.mmu.ac.uk/623277/
Version: Published Version
Publisher: Springer Verlag
DOI: https://doi.org/10.1007/s11357-014-9673-9
Usage rights: Creative Commons: Attribution 4.0

Please cite the published version
Associations between \textit{APOE} and low-density lipoprotein cholesterol genotypes and cognitive and physical capability: the HALCyon programme

Tamuno Alfred \cdot Yoav Ben-Shlomo \cdot Rachel Cooper \cdot Rebecca Hardy \cdot Cyrus Cooper \cdot Ian J. Deary \cdot Jane Elliott \cdot Ian NM Day \cdot Christopher Cooper \cdot Avan Aihie Sayer \cdot John M. Starr \cdot Diana Kuh \cdot Rachel Cooper \cdot Rebecca Hardy \cdot Cyrus Cooper \cdot Ian J. Deary \cdot Jane Elliott \cdot Ian NM Day \cdot Christopher Cooper \cdot Avan Aihie Sayer \cdot John M. Starr \cdot Diana Kuh

Received: 2 September 2013 /Accepted: 18 June 2014 /Published online: 30 July 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

\textbf{Abstract} The \textit{APOE} ε2/3/4 genotype has been associated with low-density lipoprotein cholesterol (LDL-C) and Alzheimer disease. However, evidence for associations with measures of cognitive performance in adults without dementia has been mixed, as it is for physical performance. Associations may also be evident in other genotypes implicated in LDL-C levels. As part of the Healthy Ageing across the Life Course (HALCyon) collaborative research programme, genotypic information was obtained for \textit{APOE} ε2/3/4, rs515135 (\textit{APOB}), rs2228671 (\textit{LDLR}) and rs629301 (\textit{SORT1}) from eight cohorts of adults aged between 44 and 90+ years. We investigated associations with four measures of cognitive (word recall, phonemic fluency, semantic fluency and search speed) and physical capability (grip strength, get up and go/walk speed, timed chair rises and ability to balance) using meta-analyses. Overall, little evidence for associations between any of the genotypes and measures of cognitive capability was observed (e.g. pooled beta for \textit{APOE} ε4 effect on semantic fluency \textit{z} score= −0.02; 95 % CI=−0.05 to 0.02; \textit{p} value=0.3; \textit{n}= 18,796). However, there was borderline evidence within studies that negative effects of \textit{APOE} ε4 on nonverbal ability measures become more apparent with age. Few
genotypic associations were observed with physical capability measures. The findings from our large investigation of middle-aged to older adults in the general population suggest that effects of APOE on cognitive capability are at most modest and are domain- and age-specific, while APOE has little influence on physical capability. In addition, other LDL-C-related genotypes have little impact on these traits.

Keywords Ageing · Apolipoprotein E · Cognition · Single nucleotide polymorphism

Introduction

Higher levels of low-density lipoprotein cholesterol (LDL-C) have been associated with a number of age-related conditions, including increased risk of coronary heart disease (Wilson et al. 1998). Although modification by diet (Kelley et al. 2012) and pharmacological interventions (Law et al. 2003) is possible, LDL-C is partly heritable (Matteini et al. 2010), with several identified genetic variants contributing to its interindividual variability. Among these, the ε2, ε3 and ε4 alleles of the APOE gene are probably the most widely studied. Encoding apolipoprotein E and playing a key role in lipid metabolism (Mahley and Rall 2000), several studies have observed that carriers of the APOE ε2 and ε4 alleles display lower and higher, respectively, levels of LDL-C compared with the most common ε3/ε3 genotype (Bennet et al. 2007). In addition, it has been long established that carriers of the ε2 alleles are at lower risk, and those with the ε4 alleles are at higher risk of Alzheimer disease (Bertram et al. 2007). Among cognitively healthy individuals, there is also evidence from many, though not all studies, that carriers of the ε4 allele perform worse in some cognitive tests and that these effects may be more pronounced in older populations (Caselli et al. 2009; Wisdom et al. 2011; Davies et al. 2014). For instance, there is little evidence to support the influence of the APOE genotype on cognitive measures in children and young people (Taylor et al. 2011; Ihle et al. 2012), though there is some mixed evidence for its influence in middle-aged (Zhao et al. 2005; Bunce et al. 2011) and older (Deary et al. 2004a) adults. In addition, there is some evidence from longitudinal studies that ε4 carriers experience greater cognitive decline in mid-life (Blair et al. 2005) and later (Schiepers et al. 2012) life. APOE may also have a role in ageing phenotypes more generally, with other associations including triglycerides, apolipoproteins, C-reactive protein (Khan et al. 2013), type 2 diabetes (Anthopoulos et al. 2010), longevity (McKay et al. 2011; Nebel et al. 2011) and Parkinson disease (Lill and Roehr).

Given that the observed associations between cognitive and physical performance measures (Deary et al. 2006; Clouston et al. 2013) may be a result of genetic influences on shared age-related pathways simultaneously leading to the impairment of both (Johnson et al. 2009), it has been hypothesised that the pleiotropic APOE genotype may also affect physical performance. However, to date, investigations into associations between APOE and physical performance have also been inconsistent, with the ε4 allele reported to be associated with slower gait speeds (Melzer et al. 2005), but not with fitness (Deary et al. 2006), frailty (Rockwood et al. 2008), or grip strength (Vasunilashorn et al. 2013) and mixed findings for disability (Hyman et al. 1996; Kulminski et al. 2008) and chair stands speed (Melzer et al. 2005; Vasunilashorn et al. 2013) in middle-aged and older adults.

Therefore, further investigations into associations between APOE and cognitive and physical performance measures are required. It is also of interest to examine whether any such effects are related to an effect on LDL-C. Given the conflicting evidence for associations between levels of LDL-C and cognitive (Yaffe et al. 2002; Packard et al. 2007) and physical performance measures (Walston et al. 2002; Blain et al. 2012), investigations of other LDL-C-related genotypes may help to elucidate
whether or not any effects are unique to APOE. Therefore, we analysed data from 23,916 participants aged between 44 and 90+ from eight UK cohorts as part of the HALCyon research programme (Healthy Ageing across the Life Course; www.halcyon.ac.uk) to investigate associations between the APOE genotype and objective measures of physical and cognitive capability, the capacity to undertake the physical and mental tasks of daily living. We also explored whether any effects are also demonstrated for other genotypes robustly associated with LDL-C (rs515135 (APOB), rs2228671 (LDLR) and rs629301 (SORT1)) in genome-wide association studies (Aulchenko et al. 2009; Teslovich et al. 2010) (GWAS).

Methods

Study populations

Participants from eight UK cohorts of the HALCyon programme were included in this report. The National Child Development Study (NCDS) has followed up all individuals born in England, Scotland and Wales during 1 week in March 1958. In 2002–2004, a Biomedical Survey was conducted during home visits by a research nurse. Following informed consent, DNA was extracted from 8,017 participants aged 44–45 years; the sample with immortalised cell line culture (n=7,526) is used here. In 2008–2009, an eighth sweep was carried out during which cognitive performance tests were conducted (Brown and Dodgeon 2010). Further details of the study are available elsewhere (Power and Elliott 2006).

The Medical Research Council National Survey of Health and Development (NSHD) comprises participants sampled from all births in a week in March 1946 and followed up since. In 1999, at age 53 years, men and women were visited by a research nurse and DNA was extracted from 2,756 members of the cohort. Details of the data collected and the several phases of the study are available on the cohort’s website (www.nshd.mrc.ac.uk) and elsewhere (Wadsworth et al. 2006).

The Whitehall II study targeted all civil servants aged between 35 and 55 years working in London in 1985–1988. In 2002–2004 (phase 7), the genetics study was established and DNA was extracted from 6,156 participants. Details of the study design and data collected have been described elsewhere (Marmot and Brunner 2005).


The English Longitudinal Study of Ageing (ELSA) comprises men and women aged 50 years and over who originally participated in the Health Survey for England in 1998, 1999 or 2001. Fieldwork began in 2002–2003 (phase I) with two yearly follow-ups, and in 2004–2005 (phase II), blood samples were provided by 6,231 participants. Details of the cohort have been published elsewhere (Marmot et al. 2003).

The Hertfordshire Cohort Study (HCS) consists of 2,997 participants born 1931–1939 and registered with a general practitioner in East, North or West Hertfordshire who attended a clinic in 1994–2004 (phase I). A second assessment took place in 2004–2005 for participants in East Hertfordshire (phase II). Further details of the study design, data collected and summaries of participant characteristics have been published (Syddall et al. 2005) and are available on its website (www.mrc.soton.ac.uk/herts).

The Boyd Orr cohort is a historical cohort study based on children surveyed in 1937–1939 in English and Scottish districts. Participants were followed up for vital status via the NHS Medical Information Research Service (MIRS) since 1948, with questionnaire administration to survivors in 1997–1998 (phase II) and a research clinic visit in 2002–2003 (phase III), during which DNA was extracted from 728 adults, of which 397 of 405 who attended specific measurement research clinics had at least one physical capability measure and one relevant genotype called for this analysis. Details of the study design and the data collected have been described on its website (http://www.bris.ac.uk/social-community-medicine/projects/boyd-orr) and elsewhere (Martin et al. 2005).
The Lothian Birth Cohort 1921 (LBC1921) participants were all born in 1921 and most completed a cognitive ability assessment at age 11 years. In 1999–2001 (wave I), at approximately 79 years old, 550 participants living in and around Edinburgh, underwent a series of cognitive and physical tests. In 2003–2005 (wave II), 321 returned at 83 years old. Details of the recruitment into the study are available on its website (www.lothianbirthcohort.ed.ac.uk) and have been published previously (Deary et al. 2004b; Deary et al. 2012).

Genotyping and quality control

Single nucleotide polymorphisms (SNPs) rs7412 and rs429358 form the APOE genotype (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4 and ε4/ε4; 19q13.32) and genotyping was carried out by KBioscience (www.lgcgenomics.com) in Boyd Orr, CaPS, HCS, NCDS and NSHD. In ELSA, two TaqMan assays (rs429358 and rs7412, Assay-On-Demand, Applied Biosystems, Geneservice Ltd, Cambridge, UK) were used and run on a 7900HT analyzer (Applied Biosystems), and genotypes indicated by the Sequence Detection Software version 2.0 (Applied Biosystems). Details have been described previously in LBC1921 (Schiepers et al. 2012) and Whitehall II (Sabia et al. 2010). Genotyping for other SNPs (rs515135 (APOB, 2p24.1), rs2228671 (LDLR, 19p13.2) and rs629301 (SORT1, 1p13.3)) in ELSA, HCS, CaPS and Boyd Orr were carried out by KBioscience, as well as for rs2228671 in NSHD. In LBC1921, information came from the Illumina Human 610-Quadv1 Chip (using proxies rs541041 for rs515135 and rs646776 for rs629301) (Houlihan et al. 2010). SNPs in NCDS came from two sources—Illumina HumanHap 550 k v3 and Illumina 1.2 M chips (using rs562338 and rs541041 as proxies for rs515135 and rs646776 as a proxy for rs629301) (Wellcome Trust Case Control Consortium 2007). Genotype information for these three SNPs in Whitehall II as well as rs515135 and rs2228671 in NSHD came from the Illumina Metabochip (www.illumina.com). Genotypic data quality was reviewed by assessing departure from the Hardy-Weinberg equilibrium (HWE), clustering quality (using KBioscience software SNPviewer on their data) and call rates.

Phenotypes

Cognitive capability

A number of cognitive performance tests in the different studies were used to assess cognitive capability. Different assessments of verbal memory (Bopp and Verhaeghen 2005) were conducted; in ELSA and NCDS, a list of 10 common words were used, with participants asked to recall the list immediately and again after a delay of around 5 min; the mean score was used in the analysis; in NSHD, 15 words were used over three trials; in Whitehall II, 20 words were used; responses in NSHD and Whitehall II were given in writing. In Whitehall II, participants recalled in writing in 1 min as many words as possible beginning with ‘S’ to assess phonemic fluency (Borkowski et al. 1967), while in LBC1921 three letters ‘C’, ‘F’ and ‘L’ were used with responses given orally. Participants were asked to recall as many animals as possible within 1 min to measure semantic fluency (Borkowski et al. 1967); responses were given orally in ELSA, NCDS, CaPS and NSHD, and in writing in Whitehall II. To assess search speed (Richards et al. 1999), 1-min letter searches among grids of letters were used, 600 letters in NSHD and 780 in ELSA and NCDS.

Physical capability

Grip strength was measured in NSHD, ELSA, HCS and LBC1921 using electronic or hydraulic dynamometers, with the best measure used in the analysis where more than one trial was conducted. Standing balance tests were conducted in the studies, with participants’ eyes open: flamingo (up to a maximum time of 30 s) (Sport 1993), in NSHD, HCS, Boyd Orr and CaPS, and side-by-side, semi-tandem and full tandem (Stevens et al. 2008) in ELSA. Ability to balance was defined in this analysis as the ability to complete 30 s of the flamingo or 5 s of the tandem test. The timed get up and go test (Podsiadlo and Richardson 1991) was carried out in HCS, Boyd Orr and CaPS and required participants to get up from a chair, walk 3 m at a normal pace, turn, walk back, turn and sit down. Timed walks over 2.44 m (8 ft) at a normal pace and 6 m at a fast pace were carried out in ELSA and LBC1921, respectively. Speeds were calculated for timed walks and get up and go, with the fastest speeds used in the analysis where more than one trial was conducted. Timed chair rises (Csuka and
McCarty (1985) involved asking participants to rise from a chair and sit back down 5 times in ELSA and HCS and 10 times in NSHD; the reciprocal of time taken in seconds $\times 100$ (Kuh et al. 2005) was used in the analysis. Further details of these measurements in these cohorts are presented elsewhere (Cooper et al. 2011).

Statistical methods

Where information on ethnicity was collected, non-European participants were excluded from analyses in order to avoid confounding from population stratification (Cordell and Clayton 2005). Within studies, linear regression analyses were conducted on the continuous traits and logistic regression analyses were conducted on the ability to balance, adjusting for age, except in the age homogeneous cohorts of NCDS, NSHD and LBC1921 as well as sex in all cohorts except CaPS. APOE genotype was analysed here in two ways: first, $\varepsilon_2+ (\varepsilon_2/\varepsilon_2$ or $\varepsilon_2/\varepsilon_3$) and $\varepsilon_4+ (\varepsilon_3/\varepsilon_4$ or $\varepsilon_4/\varepsilon_4$) were compared with $\varepsilon_3/\varepsilon_3$; second, $\varepsilon_4+ (\varepsilon_3/\varepsilon_4$ and $\varepsilon_4/\varepsilon_4$) was compared with non-$\varepsilon_4$ ($\varepsilon_2/\varepsilon_2$, $\varepsilon_2/\varepsilon_3$ and $\varepsilon_3/\varepsilon_3$). Due to the differences observed on LDL-C for carriers of the $\varepsilon_2$ and $\varepsilon_4$ alleles (Bennet et al. 2007), the $\varepsilon_2/\varepsilon_4$ genotype was excluded from the APOE analysis. Additive models were used for SNPs rs515135 (APOB), rs2228671 (LDLR) and rs629301 (SORT1), with genotypes coded as 0, 1 and 2 for the number of LDL-raising alleles. Likelihood ratio tests were used to compare the fit of the additive models compared with the full genotype model. Allelic scores were derived from counts of the number of APOE $\varepsilon_4$ or LDL-C-raising alleles. For continuous traits, the normality of the standardised residuals was inspected with distributional diagnostic plots. For the harmonisation of continuous traits that were used to obtain pooled estimates of the genotypic effects, z score units were calculated in each study by subtracting the overall mean for z scores is 0 and standard deviation 1. Two-step (Riley et al. 2010) meta-analyses using a random-effects model were performed to obtain pooled genotypic effects. The $\hat{P}$ measure was used to quantify heterogeneity (Higgins et al. 2003). Analyses of the interaction between $\varepsilon_4$ carrier status and age within studies were also conducted. Where outcomes were collected at more than one phase, within-study analyses were performed on the annual change in scores using differences between the most recent and earliest measure available. Finally, the calculation of z scores, for the continuous traits, and the main analyses were repeated in men and women separately. Reporting of the analyses met the appropriate items of recommended checklists (Stroup et al. 2000; Little et al. 2009). A two-tailed significance level of $p<0.05$ was used as evidence of statistical significance. Statistical analysis was performed in Stata 12.1 (StataCorp LP). Quanto (Gauderman and Morrison 2006) was used for power calculations.

Results

Cohort summaries and genotyping quality

A total of 23,916 adults aged between 44 and 90+ years had at least one relevant genotype and phenotype available (Table 1). Allelic frequencies were similar across the studies. Of the 23,061 participants with available APOE data, the genotypic frequencies were as follows: $\varepsilon_2/\varepsilon_2—0.6\%$, $\varepsilon_2/\varepsilon_3—12.3\%$, $\varepsilon_2/\varepsilon_4—2.6\%$, $\varepsilon_3/\varepsilon_3—58.5\%$, $\varepsilon_3/\varepsilon_4—23.6\%$ and $\varepsilon_4/\varepsilon_4—2.4\%$. The HWE condition was met in all studies for all polymorphisms ($p$ values $>0.1$), except for rs515135 (APOB) and rs2228671 (LDLR) in NSHD and rs515135 (APOB) in ELSA ($p$ values $=0.04$). Summaries of measures of cognitive and physical capability are presented in Table S1.

Associations between APOE genotypes and cognitive capability

Figures S1–S4 present the associations between the cognitive capability measures and $\varepsilon_2+ and \varepsilon_4+$, adjusting for age and sex, using $\varepsilon_3/\varepsilon_3$ as the reference group in the cross-sectional analyses. There was no evidence for associations in the pooled analyses. Within studies, there was evidence for negative effects of $\varepsilon_2+$ and $\varepsilon_4+$ in NSHD and ELSA, respectively, on word recall (Figure S1), and of $\varepsilon_2+$ in ELSA on semantic fluency (Figure S3). Table 2 shows that there was no evidence for associations between APOE and the cognitive capability measures when comparing carriers of the $\varepsilon_4$ allele with noncarriers. Table S2 presents the findings of the interactions between the $\varepsilon_4$ allele and age within the studies. In ELSA, there was some evidence that a negative effect of $\varepsilon_4$ on word recall increases with age ($p$ value $=0.04$) and borderline evidence for this on search speed ($p$ value $=0.08$). There was some evidence that the effects of $\varepsilon_4$ allele on word recall differs between men and women ($p$ value for
heterogeneity=0.009; Figure S5). There was no evidence for heterogeneity between men and women for other outcomes (p values>0.1; data not shown). For the few studies with data available, there was no strong evidence that the ε4 allele was associated with cognitive decline within the time periods investigated (Table S3).

**Table 1** Summary of sex, age and LDL-related genotypes by cohort

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>NCDS</th>
<th>NSHD</th>
<th>Whitehall II</th>
<th>CaPS</th>
<th>ELSA</th>
<th>HCS</th>
<th>Boyd Orr</th>
<th>LBC1921</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>7,363</td>
<td>2,674</td>
<td>3,143</td>
<td>1,318</td>
<td>5,612</td>
<td>2,893</td>
<td>397</td>
<td>516</td>
<td>23,916</td>
</tr>
<tr>
<td>Male, %</td>
<td>50</td>
<td>50</td>
<td>77</td>
<td>100</td>
<td>46</td>
<td>53</td>
<td>45</td>
<td>41</td>
<td>55</td>
</tr>
<tr>
<td>Age^a in years, median (range)</td>
<td>44</td>
<td>53</td>
<td>59 (50–73)</td>
<td>61 (52–71)</td>
<td>65 (52–90+)</td>
<td>66 (59–73)</td>
<td>70 (64–82)</td>
<td>79 (77–80)</td>
<td>56 (44–90+)</td>
</tr>
<tr>
<td>APOE ε4 carrier statusb, %</td>
<td>27</td>
<td>28</td>
<td>26</td>
<td>26</td>
<td>26</td>
<td>26</td>
<td>24</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>LDL-C-raising allele frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs515135 APOB, C</td>
<td>0.82</td>
<td>0.82</td>
<td>0.82</td>
<td>0.82</td>
<td>0.82</td>
<td>0.82</td>
<td>0.82</td>
<td>0.85</td>
<td>0.82</td>
</tr>
<tr>
<td>rs2228671 LDLR, C</td>
<td>0.87</td>
<td>0.88</td>
<td>0.87</td>
<td>0.88</td>
<td>0.88</td>
<td>0.88</td>
<td>0.88</td>
<td>0.88</td>
<td>0.87</td>
</tr>
<tr>
<td>rs629301 SORT1, A</td>
<td>0.78</td>
<td>0.77</td>
<td>0.79</td>
<td>0.77</td>
<td>0.78</td>
<td>0.78</td>
<td>0.77</td>
<td>0.75</td>
<td>0.78</td>
</tr>
</tbody>
</table>

Number of participants represents those with available data for at least one phenotype and at least one genotype

CaPS Caerphilly Prospective Study, ELSA English Longitudinal Study of Ageing, HCS Hertfordshire Cohort Study, LBC1921 Lothian Birth Cohort 1921, NCDS National Child Development Study, NSHD National Survey of Health and Development

^a Age at phase from which the majority of variables are taken, i.e. Boyd Orr: III; CaPS: III; ELSA: II; HAS: I; HCS: I; LBC1921: I; NCDS: Biomedical Survey (2002); NSHD: 1999 Collection; Whitehall II: VII

^b ε4 carrier defined as ε3/ε4 or ε4/ε4; ε2/ε4 excluded from denominator

There was some evidence that the LDL-C-raising allele of rs2228671 (LDLR) was associated with lower semantic fluency scores (Table 2, Figure S6). There was no evidence for any other associations between the SNPs and measures of cognitive capability (Table 2). Table S4 that shows there was no evidence for associations between any of the measures and the allelic count of the number of LDL-C-raising and ε4 alleles. There was no evidence for differences in genotypic effects by sex for the SNPs (p values>0.06; data not shown).

Associations between APOB, LDLR and SORT1 genotypes and physical capability

Figures S7 to S10 show that there was no strong evidence of associations in the pooled analyses between the physical capability measures and ε2+ and ε4+ adjusting for age and sex, compared with ε3/ε3 in the cross-sectional analyses. Within studies, there was evidence in ELSA that participants with ε4+ had slower chair rise times than those with ε3/ε3 (Figure S9). There was no evidence that carriers of ε4 had poorer performance than noncarriers in the pooled analyses (Table 3). Table S5 shows that there was no evidence for interactions between the ε4 allele and age within the studies. There was no evidence for heterogeneity between men and women in the effects of the ε4 allele for these measures (p values>0.6; data not shown). In the longitudinal analyses, there was evidence in ELSA that the ε4 allele was associated with decline in timed walk speed (p value=0.02; Table S6).

Associations between APOB, LDLR and SORT1 genotypes and physical capability

Table 3 shows that there was no evidence for associations between the SNPs and measures of physical capability. Table S7 shows that there was evidence for associations between the allelic count of the number of LDL-C-raising and ε4 alleles and poorer timed chair rises (p value=0.01). There was some evidence that the effect of the C allele of rs515135 (APOB) on timed chair rises differed by sex, with an inverse association observed in females only (p value for heterogeneity=0.01; Figure S11). There was also evidence for heterogeneity by sex for the effects of rs2228671 (LDLR) on ability to balance (p value for heterogeneity=0.04; Figure S12).
Table 2  Summary of pooled associations between LDL-C-related genotypes and cognitive capability

<table>
<thead>
<tr>
<th>Measure</th>
<th>Genotype</th>
<th>Beta (95% CI)</th>
<th>p</th>
<th>$\hat{I}^2$; Het p</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Word recall</td>
<td>$	extit{APOE} \varepsilon 4$</td>
<td>-0.01 (-0.06–0.04)</td>
<td>0.67</td>
<td>46.0; 0.14</td>
<td>17,513</td>
</tr>
<tr>
<td></td>
<td>$\text{rs515135 APOB}$</td>
<td>-0.02 (-0.04–0.01)</td>
<td>0.23</td>
<td>0.0; 0.67</td>
<td>16,473</td>
</tr>
<tr>
<td></td>
<td>$\text{rs2228671 LDLR}$</td>
<td>0.01 (-0.02–0.04)</td>
<td>0.49</td>
<td>0.0; 0.97</td>
<td>16,481</td>
</tr>
<tr>
<td></td>
<td>$\text{rs629301 SORT1}$</td>
<td>0.01 (-0.02–0.03)</td>
<td>0.52</td>
<td>0.0; 0.97</td>
<td>16,494</td>
</tr>
<tr>
<td>Phonemic fluency</td>
<td>$	extit{APOE} \varepsilon 4$</td>
<td>-0.01 (-0.16–0.14)</td>
<td>0.89</td>
<td>53.6; 0.14</td>
<td>3,528</td>
</tr>
<tr>
<td></td>
<td>$\text{rs515135 APOB}$</td>
<td>0.00 (-0.07–0.07)</td>
<td>0.96</td>
<td>7.8; 0.30</td>
<td>3,638</td>
</tr>
<tr>
<td></td>
<td>$\text{rs2228671 LDLR}$</td>
<td>-0.03 (-0.10–0.05)</td>
<td>0.52</td>
<td>6.8; 0.30</td>
<td>3,638</td>
</tr>
<tr>
<td></td>
<td>$\text{rs629301 SORT1}$</td>
<td>-0.01 (-0.06–0.05)</td>
<td>0.83</td>
<td>0.0; 0.88</td>
<td>3,636</td>
</tr>
<tr>
<td>Semantic fluency</td>
<td>$	extit{APOE} \varepsilon 4$</td>
<td>-0.02 (-0.05–0.02)</td>
<td>0.31</td>
<td>0.0; 0.98</td>
<td>18,796</td>
</tr>
<tr>
<td></td>
<td>$\text{rs515135 APOB}$</td>
<td>-0.02 (-0.05–0.01)</td>
<td>0.16</td>
<td>0.0; 0.97</td>
<td>17,761</td>
</tr>
<tr>
<td></td>
<td>$\text{rs2228671 LDLR}$</td>
<td>-0.03 (-0.06–0.00)</td>
<td>0.048</td>
<td>0.0; 0.51</td>
<td>17,766</td>
</tr>
<tr>
<td></td>
<td>$\text{rs629301 SORT1}$</td>
<td>0.01 (-0.04–0.05)</td>
<td>0.83</td>
<td>66.8; 0.02</td>
<td>17,774</td>
</tr>
<tr>
<td>Search speed</td>
<td>$	extit{APOE} \varepsilon 4$</td>
<td>0.00 (-0.05–0.06)</td>
<td>0.91</td>
<td>54.6; 0.11</td>
<td>14,348</td>
</tr>
<tr>
<td></td>
<td>$\text{rs515135 APOB}$</td>
<td>-0.02 (-0.05–0.01)</td>
<td>0.26</td>
<td>0.0; 0.82</td>
<td>13,229</td>
</tr>
<tr>
<td></td>
<td>$\text{rs2228671 LDLR}$</td>
<td>0.01 (-0.02–0.05)</td>
<td>0.54</td>
<td>0.0; 0.81</td>
<td>13,235</td>
</tr>
<tr>
<td></td>
<td>$\text{rs629301 SORT1}$</td>
<td>0.00 (-0.05–0.05)</td>
<td>0.90</td>
<td>64.7; 0.06</td>
<td>13,250</td>
</tr>
</tbody>
</table>

Coefficients based on $z$ scores and adjusted for age and sex. Coefficients for $\textit{APOE} \varepsilon 4$: carrier vs. non-$\varepsilon 4$ carrier; else per LDL-C-raising allele

Table 3  Summary of pooled associations between LDL-C-related genotypes and physical capability

<table>
<thead>
<tr>
<th>Measure</th>
<th>Genotype</th>
<th>Beta (95% CI)</th>
<th>p</th>
<th>$\hat{I}^2$; Het p</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grip strength</td>
<td>$\textit{APOE} \varepsilon 4$</td>
<td>0.01 (-0.02–0.05)</td>
<td>0.42</td>
<td>30.7; 0.23</td>
<td>10,646</td>
</tr>
<tr>
<td></td>
<td>$\text{rs515135 APOB}$</td>
<td>0.00 (-0.04–0.03)</td>
<td>0.81</td>
<td>41.5; 0.16</td>
<td>11,247</td>
</tr>
<tr>
<td></td>
<td>$\text{rs2228671 LDLR}$</td>
<td>0.01 (-0.01–0.04)</td>
<td>0.40</td>
<td>0.0; 0.65</td>
<td>11,234</td>
</tr>
<tr>
<td></td>
<td>$\text{rs629301 SORT1}$</td>
<td>-0.01 (-0.03–0.02)</td>
<td>0.61</td>
<td>34.1; 0.21</td>
<td>11,242</td>
</tr>
<tr>
<td>Get up and go/walk speed</td>
<td>$\textit{APOE} \varepsilon 4$</td>
<td>-0.02 (-0.07–0.04)</td>
<td>0.57</td>
<td>7.8; 0.36</td>
<td>6,810</td>
</tr>
<tr>
<td></td>
<td>$\text{rs515135 APOB}$</td>
<td>0.00 (-0.05–0.06)</td>
<td>0.90</td>
<td>30.6; 0.22</td>
<td>7,291</td>
</tr>
<tr>
<td></td>
<td>$\text{rs2228671 LDLR}$</td>
<td>0.04 (-0.06–0.13)</td>
<td>0.47</td>
<td>67.6; 0.01</td>
<td>7,277</td>
</tr>
<tr>
<td></td>
<td>$\text{rs629301 SORT1}$</td>
<td>0.01 (-0.03–0.04)</td>
<td>0.73</td>
<td>0.0; 0.42</td>
<td>7,281</td>
</tr>
<tr>
<td>Timed chair rises</td>
<td>$\textit{APOE} \varepsilon 4$</td>
<td>-0.04 (-0.10–0.02)</td>
<td>0.18</td>
<td>37.8; 0.20</td>
<td>8,159</td>
</tr>
<tr>
<td></td>
<td>$\text{rs515135 APOB}$</td>
<td>-0.03 (-0.07–0.01)</td>
<td>0.11</td>
<td>0.0; 0.85</td>
<td>8,601</td>
</tr>
<tr>
<td></td>
<td>$\text{rs2228671 LDLR}$</td>
<td>0.00 (-0.05–0.04)</td>
<td>0.86</td>
<td>2.4; 0.36</td>
<td>8,598</td>
</tr>
<tr>
<td></td>
<td>$\text{rs629301 SORT1}$</td>
<td>-0.02 (-0.06–0.01)</td>
<td>0.16</td>
<td>0.0; 0.47</td>
<td>8,601</td>
</tr>
<tr>
<td>Ability to balance ≥5 s</td>
<td>$\textit{APOE} \varepsilon 4$</td>
<td>1.02 (0.88–1.17)</td>
<td>0.80</td>
<td>0.0; 0.63</td>
<td>8,696/10,114</td>
</tr>
<tr>
<td></td>
<td>$\text{rs515135 APOB}$</td>
<td>1.01 (0.91–1.13)</td>
<td>0.86</td>
<td>0.0; 0.67</td>
<td>9,131/10,654</td>
</tr>
<tr>
<td></td>
<td>$\text{rs2228671 LDLR}$</td>
<td>1.04 (0.92–1.18)</td>
<td>0.54</td>
<td>0.0; 0.70</td>
<td>9,122/10,643</td>
</tr>
<tr>
<td></td>
<td>$\text{rs629301 SORT1}$</td>
<td>0.97 (0.87–1.07)</td>
<td>0.49</td>
<td>0.0; 0.92</td>
<td>9,139/10,652</td>
</tr>
</tbody>
</table>

Coefficients for continuous outcomes based on $z$ scores. Adjusted for age and sex. Coefficients for $\textit{APOE} \varepsilon 4$: carrier vs. non-$\varepsilon 4$ carrier; else per LDL-C-raising allele.
Discussion

In this investigation of 23,916 adults aged between 44 and 90+ from eight UK cohorts, we examined the genotypic effects of the APOE ε2/3/4 genotype on measures of cognitive and physical capability, as well as those of three other LDL-C-related genotypes: rs515135 (APOB), rs2228671 (LDLR) and rs629301 (SORT1). For the four cognitive capability measures studied (word recall, phonemic fluency, semantic fluency and search speed), we found little evidence for associations with APOE genotype (Table 2). However, within-study investigations into interactions between ε4 and age provided suggestive evidence for an adverse effect of ε4 on word recall that increased with age ($p$ value=0.044, $n=4,971$) as well as suggestive evidence for this on search speed in the largest age-heterogeneous cohort ($p$ value=0.08, $n=4,901$; Table S2). In the longitudinal analyses, we observed no evidence that the ε4 allele was associated with cognitive decline. Investigations into the other genotypes revealed only borderline evidence for an association between the LDL-C-raising allele of rs2228671 (LDLR) and reduced semantic fluency ($p$ value=0.048, $n=17,766$). There was little evidence to support associations between the APOE genotype and our physical capability measures (grip strength, timed get up and go/walk speed, timed chair rises and ability to balance) in the cross-sectional analysis and no evidence that genotypic effects vary by age. In the longitudinal analysis, there was evidence from ELSA that the ε4 allele was associated with decline in timed walk speeds ($p$ value=0.02, $n=2,195$; Table S6). We found little evidence for associations between the other LDL-C-related genotypes and physical capability (Table 3).

Previous investigations into associations between the APOE genotype and measures of cognitive performance have produced mixed findings, possibly reflecting differences in cognitive domains and age (Wisdom et al. 2011). Meta-analyses of previous studies have found evidence for small adverse effects of the ε4 allele on some cognitive domains, including episodic memory, as well as evidence that this effect may increase with age (Wisdom et al. 2011). An increasing effect with age has also been seen in a study of over 10,000 Korean older adults (Shin et al. 2014). However, no evidence was found for effects on measures on verbal ability (Wisdom et al. 2011). Results from our investigations on APOE are consistent with many of those findings, with evidence for an interaction between ε4 and age on a measure of episodic memory and word recall and no evidence for any effects on our measures of verbal ability: semantic and phonemic fluency. Previous studies have observed a greater cognitive decline among carriers of the ε4 allele compared with noncarriers; in particular, there is evidence from a middle-aged cohort for differences in delayed word recall over 6 years (Blair et al. 2005), and a longitudinal study showed that declines in memory scores may be apparent before 60 years (Davies et al. 2014). Our own investigation from the model in ELSA suggested a detectable difference from around 55 years. Fewer investigations have been reported on the associations between APOE and measures of physical performance; however, findings include no association with athletic performance (Tsianos et al. 2010) and associations between ε4 and slower gait speeds from a study of 1,262 adults aged over 65 years (Melzer et al. 2005). Our larger investigation found evidence to support a role of APOE in decline in walk speeds over a 4-year period in one study but little evidence for associations with physical capability from cross-sectional analysis. Differences have been observed in the genotypic frequencies of rs11668477 in LDLR for mild cognitive impairment status in a small study of 114 cases and 92 controls (Liu et al. 2012). We believe that this is the largest investigation between APOB, LDLR and SORT1 genotypes and measures of cognitive and physical performance.

Our large investigation into associations between the APOE genotype on cognitive capability measures provided only modest evidence for an adverse effect of the ε4 allele. There was also little evidence from the three other investigated LDL-C-related genotypes, suggesting that the small effects of APOE observed previously on some cognitive measures in population-based studies may not extend to genotypes implicated in LDL-C levels as a whole. However, the lack of evidence from our studies for these other SNPs may reflect a lack of power to observe possible small effects. Sample size calculations demonstrated around 11,000 individuals would be required to detect a beta coefficient of 0.05 ± score units with 80 % power at the 5 % significance level for a SNP such as rs515135 (APOB) using an observed minor allele frequency of 0.18. We were sufficiently powered to detect differences as small as this for three of our cognitive measures; however, the observed pooled coefficients were much smaller. There are hypothesised mechanisms through which APOE may...
affect cognitive performance in non-demented adults other than through LDL-C, for instance, ε4/ε4 has been associated with increased rate of hippocampal volume loss (Crivello et al. 2010) and increased white matter hyperintensity burden (Schilling et al. 2013). Furthermore, APOE has been associated with several other ageing phenotypes (Khan et al. 2013). Our results suggest that these mechanisms might not lead to cognitive differences at a population level. Similar to the reports on cognitive performance (Yaffe et al. 2002; Packard et al. 2007), associations between measures of LDL-C and physical performance in the literature have been mixed, with higher levels associated with slower walking speeds (Walston et al. 2002), but some evidence that it may be protective against frailty (Blain et al. 2012). Our findings from other LDL-C-related genotypes suggest that LDL-C may not be an important mechanism through which APOE could affect physical performance. However, other potential pathways include the modest effects on specific cognitive measures and their decline and effects on bone-related phenotypes, though evidence for the latter is inconsistent (Peter et al. 2011; Tolonen et al. 2011).

Despite the size of our study, large age range and the inclusion of other LDL-C-related genotypes, there are some limitations. First, our ability to detect effects of our genotypes on decline in cognitive and physical capability may have been hindered by generally short intervals between measures in the cohorts (often around four years). Second, despite the important cognitive measures included here, there may be other cognitive domains which may be influenced by the APOE genotype. Third, although we only observed modest evidence for a detrimental impact of the ε4 allele on cognitive outcomes, it is possible that an effect may be influenced a likely higher proportion of preclinical dementia cases among the ε4 carriers. However, it is possible that APOE also affects non-pathological cognitive ageing (Davies et al. 2014). Fourth, we did not conduct investigations into the differential effects among each of the six APOE genotypes; however, given we observed only modest evidence for differences between ε4 and non-ε4 carriers, it is unlikely that this study would have been sufficiently powered to observe any of the putatively smaller differences. Furthermore, larger meta-analyses were unable to detect differences between the effects of ε3/ε4 and ε4/ε4 on several cognitive domains (Wisdom et al. 2011).

Conclusion

This large, multi-cohort investigation into associations between APOE ε2/3/4 genotype, three other LDL-C-related SNPs and measures of cognitive and physical capability provided little support for anything but modest effects of these genotypes on these traits in middle-aged to older adults.

Acknowledgments We thank Kate Birnie, Vanessa Cox, Philip Curran, Nikki Graham, Karen Jameson, Jon Johnson, Aida Sanchez, Imran Shah, Andrew Taylor and Andrew Wong for providing the data. We acknowledge the support of the Medical Research Council and Arthritis Research (UK). The Boyd Orr DNA bank was funded by the Wellcome Trust (Grant number: GR068468MA). Follow-up of the Boyd Orr cohort was supported by grants from the Wellcome Trust, World Cancer Research Fund, Research into Ageing and the British Heart Foundation. The Caerphilly Prospective study was conducted by the former MRC Epidemiology Unit (South Wales) and funded by the Medical Research Council of the United Kingdom. The Department of Social and Community Medicine, University of Bristol now maintains the archive. Samples were from the English Longitudinal Study of Ageing (ELSA) DNA Repository (EDNAR) and received support under a grant (AG1764406S1) awarded by the National Institute on Ageing (NIA). ELSA was developed by a team of researchers based at the National Centre for Social Research, University College London and the Institute of Fiscal Studies. The data were collected by the National Centre for Social Research. The Hertfordshire Cohort Study was conducted by the MRC Lifecourse Epidemiology Unit at the University of Southampton and funded by the Medical Research Council and the University of Southampton. We thank the Lothian Birth Cohort 1921 participants. We thank the Scottish Council for Research in Education for allowing access to the Scottish Mental Survey 1932. The Biotechnology and Biological Sciences Research Council (BBSRC) funded the phenotypic data collection and DNA preparation (project grant 15/SAG09977) and GWAS (project grant BB/ F019394/1). The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (Centre grant G0700704/84698). Funding from the BBSRC, Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC) and Medical Research Council (MRC) is gratefully acknowledged. The MRC NSHD is funded by the UK Medical Research Council. NCDS 1958 British birth cohort: phenotype measures (blood pressure, etc.) and DNA collection were funded by the MRC (project grant G0000934) and creation of immortalised cell lines by Wellcome Trust Grant 068545/ Z/02. The NCDS cohort is managed by the Centre for Longitudinal Studies, Department of Quantitative Social Sciences, Institute of Education, London, which is funded as an ESRC Resource Centre. The MRC Centre of Epidemiology for Child Health is funded by the MRC. Great Ormond Street Hospital /University College London, Institute of Child Health receives a proportion of funding from the Department of Health’s National Institute of Health Research (‘Biomedical Research Centres’ funding). The Whitehall II funding were from the Medical Research Council (K013351); British Heart
Conflict of interest  The authors declare no competing interests.

Open Access  This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References


Springer


Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678. doi:10.1038/nature05911


